Decreased Expression of IGFBP7 Was a Poor Prognosis Predictor for Gastric Cancer Patients

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2014 Jun 5

PMID 24894674

Citations 13

Authors

Long Liu

Zhihui Yang

Weixing Zhang

Bing Yan

Qunhao Gu

Jianpeng Jiao

XiaoQiang Yue

Affiliations

Soon will be listed here.

Abstract

Increasing evidence indicated that insulin-like growth factor binding protein 7 (IGFBP7) was regarded as a potential tumor suppressor in various human cancers, but its role in gastric cancer is still largely unknown. In the present study, we performed a retrospective study which includes 247 gastric cancer patients. Among them, the IGFBP7 expression was detected by qRT-PCR in 138 cases of gastric cancer and adjacent non-tumor tissues and was further correlated with the expression of p53, Ki-67, and the clinicopathologic features. The results indicated that both IGFBP7 mRNA and protein in gastric cancer tissues were significantly lower than those in the adjacent non-tumor tissues. Additionally, the expression of IGFBP7 was correlated with the depth of invasion, lymph node metastasis, and TNM stage. Interestingly, the expression of IGFBP7 was negatively associated with Ki-67 (r = -0.227, P < 0.001) but positively associated with p53 (r = 0.140, P = 0.028). Univariate analysis showed that low expression of IGFBP7 was associated with poor prognosis (P < 0.001), and multivariate analysis showed that IGFBP7 (HR = 1.87; 95 % CI 1.65-2.17), distant metastasis (HR = 2.68; 95 % CI 1.58-4.56), and tumor size (HR = 1.45; 95 % CI 0.90-2.32) were independent prognostic factors for gastric cancer patients. These results demonstrated that IGFBP7 was downregulated in gastric cancer, and its low expression was potentially correlated with increased cancer cell proliferation and could be used to predicate poor prognosis in these patients.

Citing Articles

IGFBP7 regulates cell proliferation and migration through JAK/STAT pathway in gastric cancer and is regulated by DNA and RNA methylation.

Mo W, Deng L, Cheng Y, Ge S, Wang J J Cell Mol Med. 2024; 28(19):e70080.

PMID: 39351597 PMC: 11443158. DOI: 10.1111/jcmm.70080.

IGFBP7 promotes gastric cancer by facilitating epithelial-mesenchymal transition of gastric cells.

Wang J, Wang X, Liu Z, Li S, Yin W Heliyon. 2024; 10(10):e30986.

PMID: 38778944 PMC: 11108983. DOI: 10.1016/j.heliyon.2024.e30986.

Analysis of IGFBP7 expression characteristics in pan-cancer and its clinical relevance to stomach adenocarcinoma.

Xu H, Wang M, Zhu S Transl Cancer Res. 2023; 12(10):2596-2612.

PMID: 37969374 PMC: 10643967. DOI: 10.21037/tcr-23-1055.

Angiogenesis modulated by CD93 and its natural ligands IGFBP7 and MMRN2: a new target to facilitate solid tumor therapy by vasculature normalization.

Li Y, Fu L, Wu B, Guo X, Shi Y, Lv C Cancer Cell Int. 2023; 23(1):189.

PMID: 37660019 PMC: 10474740. DOI: 10.1186/s12935-023-03044-z.

The diagnostic value of serum insulin-like growth factor binding protein 7 in gastric cancer.

Liu C, Wu F, Zhuang Y, Huang X, Li X, Qu Q PeerJ. 2023; 11:e15419.

PMID: 37304887 PMC: 10249617. DOI: 10.7717/peerj.15419.

References

Sarela A, Verbeke C, Ramsdale J, Davies C, Markham A, Guillou P . Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer. 2002; 86(6):886-92. PMC: 2364160. DOI: 10.1038/sj.bjc.6600133. View

Benatar T, Yang W, Amemiya Y, Evdokimova V, Kahn H, Holloway C . IGFBP7 reduces breast tumor growth by induction of senescence and apoptosis pathways. Breast Cancer Res Treat. 2011; 133(2):563-73. DOI: 10.1007/s10549-011-1816-4. View

Amemiya Y, Yang W, Benatar T, Nofech-Mozes S, Yee A, KAHN H . Insulin like growth factor binding protein-7 reduces growth of human breast cancer cells and xenografted tumors. Breast Cancer Res Treat. 2010; 126(2):373-84. DOI: 10.1007/s10549-010-0921-0. View

Yamamoto S, Tomita Y, Hoshida Y, Morooka T, Nagano H, Dono K . Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res. 2004; 10(8):2846-50. DOI: 10.1158/1078-0432.ccr-02-1441. View

Tomimaru Y, Eguchi H, Wada H, Kobayashi S, Marubashi S, Tanemura M . IGFBP7 downregulation is associated with tumor progression and clinical outcome in hepatocellular carcinoma. Int J Cancer. 2011; 130(2):319-27. DOI: 10.1002/ijc.25994. View

Lin Y, Ueda J, Kikuchi S, Totsuka Y, Wei W, Qiao Y . Comparative epidemiology of gastric cancer between Japan and China. World J Gastroenterol. 2011; 17(39):4421-8. PMC: 3218157. DOI: 10.3748/wjg.v17.i39.4421. View

Yamasawa K, Nio Y, Dong M, Yamaguchi K, Itakura M . Clinicopathological significance of abnormalities in Gadd45 expression and its relationship to p53 in human pancreatic cancer. Clin Cancer Res. 2002; 8(8):2563-9. View

Burger A, Leyland-Jones B, Banerjee K, Spyropoulos D, Seth A . Essential roles of IGFBP-3 and IGFBP-rP1 in breast cancer. Eur J Cancer. 2005; 41(11):1515-27. DOI: 10.1016/j.ejca.2005.04.023. View

Wang W . Enhancing the treatment of metabolic syndrome with integrative medicine. J Integr Med. 2013; 11(3):153-6. DOI: 10.3736/jintegrmed2013033. View

10.

Sprenger C, Damon S, Hwa V, Rosenfeld R, Plymate S . Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) is a potential tumor suppressor protein for prostate cancer. Cancer Res. 1999; 59(10):2370-5. View

11.

Brenner H, Rothenbacher D, Arndt V . Epidemiology of stomach cancer. Methods Mol Biol. 2008; 472:467-77. DOI: 10.1007/978-1-60327-492-0_23. View

12.

Liu D, Zhang Z, Kong C . High FOXM1 expression was associated with bladder carcinogenesis. Tumour Biol. 2013; 34(2):1131-8. DOI: 10.1007/s13277-013-0654-x. View

13.

Vizioli M, Sensi M, Miranda C, Cleris L, Formelli F, Anania M . IGFBP7: an oncosuppressor gene in thyroid carcinogenesis. Oncogene. 2010; 29(26):3835-44. DOI: 10.1038/onc.2010.136. View

14.

Walker G, Antoniono R, Ross H, Paisley T, Oh Y . Neuroendocrine-like differentiation of non-small cell lung carcinoma cells: regulation by cAMP and the interaction of mac25/IGFBP-rP1 and 25.1. Oncogene. 2005; 25(13):1943-54. DOI: 10.1038/sj.onc.1209213. View

15.

Sun D, Liu L, Jiao J, Wei P, Jiang L, Xu L . Syndrome characteristics of traditional Chinese medicine: summary of a clinical survey in 767 patients with gastric cancer. Zhong Xi Yi Jie He Xue Bao. 2010; 8(4):332-40. DOI: 10.3736/jcim20100406. View

16.

Sprenger C, Vail M, Evans K, Simurdak J, Plymate S . Over-expression of insulin-like growth factor binding protein-related protein-1(IGFBP-rP1/mac25) in the M12 prostate cancer cell line alters tumor growth by a delay in G1 and cyclin A associated apoptosis. Oncogene. 2002; 21(1):140-7. DOI: 10.1038/sj.onc.1205021. View

17.

Sato Y, Chen Z, Miyazaki K . Strong suppression of tumor growth by insulin-like growth factor-binding protein-related protein 1/tumor-derived cell adhesion factor/mac25. Cancer Sci. 2007; 98(7):1055-63. PMC: 11158653. DOI: 10.1111/j.1349-7006.2007.00502.x. View

18.

Barbareschi M, Maisonneuve P, Aldovini D, Cangi M, Pecciarini L, Mauri F . High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer. 2003; 98(3):474-83. DOI: 10.1002/cncr.11515. View

19.

Yamanaka Y, Wilson E, Rosenfeld R, Oh Y . Inhibition of insulin receptor activation by insulin-like growth factor binding proteins. J Biol Chem. 1998; 272(49):30729-34. DOI: 10.1074/jbc.272.49.30729. View

20.

Ruan W, Lin J, Xu E, Xu F, Ma Y, Deng H . IGFBP7 plays a potential tumor suppressor role against colorectal carcinogenesis with its expression associated with DNA hypomethylation of exon 1. J Zhejiang Univ Sci B. 2006; 7(11):929-32. PMC: 1635813. DOI: 10.1631/jzus.2006.B0929. View